نتایج جستجو برای: pdgfra

تعداد نتایج: 1003  

Journal: :Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 2014
I Kocáková I Kocák S Spelda P Fabian A Jurečková R Vyzula

Inoperable c- kit negative gastrointestinal stromal tumor (GIST) is commonly considered to be highly resistant to systemic therapy. We present a case of a woman with an abdominal sarcomalike tumor diagnosed at the age of 26. The patient underwent several surgical procedures and courses of cytostatic therapy without any substantial effect. Later, the tumor was reclassified as c- kit negative GIS...

2011
Erinn Downs-Kelly Brian P. Rubin

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract and are diverse not only in their clinical behavior but also in their histologic appearance. GISTs are insensitive to conventional sarcoma chemotherapy and radiation. However GISTs are sensitive to small-molecule tyrosine kinase inhibitors as 85-90% of GISTs have KIT or platelet-deriv...

Journal: :Atlas of Genetics and Cytogenetics in Oncology and Haematology 2011

2011
Jeanny H. Wang Jerzy Lasota Markku Miettinen

Gastrointestinal Stromal Tumor (GIST) is the most common mesenchymal tumor of the digestive tract. GISTs develop with relatively high incidence in patients with Neurofibromatosis-1 syndrome (NF1). Mutational activation of KIT or PDGFRA is believed to be a driving force in the pathogenesis of familial and sporadic GISTs. Unlike those tumors, NF1-associated GISTs do not have KIT or PGDFRA mutatio...

2010
Jan Zietsch Nicolas Ziegenhagen Frank L. Heppner David Reuss Andreas von Deimling Nikola Holtkamp

BACKGROUND Malignant peripheral nerve sheath tumors (MPNST) are highly aggressive tumors which originate from Schwann cells and develop in about 10% of neurofibromatosis type 1 (NF1) patients. The five year survival rate is poor and more effective therapies are needed. Sunitinib is a drug targeting receptor tyrosine kinases (RTK) like PDGFRalpha, c-Kit and VEGFR-2. These genes are structurally ...

2010
Mara Silva Isabel Veiga Franclim R Ribeiro Joana Vieira Carla Pinto Manuela Pinheiro Bárbara Mesquita Catarina Santos Marta Soares José Dinis Lúcio Santos Paula Lopes Mariana Afonso Carlos Lopes Manuel R Teixeira

BACKGROUND Oncogenic point mutations in KIT or PDGFRA are recognized as the primary events responsible for the pathogenesis of most gastrointestinal stromal tumors (GIST), but additional genomic alterations are frequent and presumably required for tumor progression. The relative contribution of such alterations for the biology and clinical behavior of GIST, however, remains elusive. METHODS I...

2016
Chih-Min Tang Tracy E. Lee Sabriya A. Syed Adam M. Burgoyne Stephanie Y. Leonard Fei Gao Jonathan C. Chan Eileen Shi Juliann Chmielecki Deborah Morosini Kai Wang Jeffrey S. Ross Michael L. Kendrick Michael R. Bardsley Martina De Siena Junhao Mao Olivier Harismendy Tamas Ordog Jason K. Sicklick

Gastrointestinal stromal tumors (GIST) arise within the interstitial cell of Cajal (ICC) lineage due to activating KIT/PDGFRA mutations. Both ICC and GIST possess primary cilia (PC), which coordinate PDGFRA and Hedgehog signaling, regulators of gastrointestinal mesenchymal development. Therefore, we hypothesized that Hedgehog signaling may be altered in human GIST and controls KIT expression. Q...

2011
Jeanny H. Wang Jerzy Lasota Markku Miettinen

Gastrointestinal Stromal Tumor (GIST) is the most common mesenchymal tumor of the digestive tract. GISTs develop with relatively high incidence in patients with Neurofibromatosis-1 syndrome (NF1). Mutational activation of KIT or PDGFRA is believed to be a driving force in the pathogenesis of familial and sporadic GISTs. Unlike those tumors, NF1-associated GISTs do not have KIT or PGDFRA mutatio...

Journal: :The American journal of surgical pathology 2009
Markku Miettinen Zeng-Feng Wang Jerzy Lasota

Gastrointestinal stromal tumors (GISTs), KIT or platelet derived growth factor receptor alpha (PDGFRA) signaling driven mesenchymal tumors of the gastrointestinal (GI)-tract and abdomen, require a precise diagnosis so that the patients may benefit from the newly introduced tyrosine kinase inhibitor drugs. The limitations of the current main tools, KIT immunohistochemistry and KIT/PDGFRA mutatio...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید